Related Experiment Video

Updated: Oct 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan

Panagiotis Kotridis1, Basile Kokkas, Michalis Karamouzis

  • 1Department of Second Cardiology, Medical School, Aristotle University of Thessaloniki, Greece.

Blood Pressure
|May 31, 2002
PubMed

Insights

The study found that irbesartan, an AT1-blocker, increases atrial natriuretic peptide (ANP) levels in patients with hypertension. This suggests a novel mechanism for its blood pressure-lowering effects.

Area of Science:

  • Cardiology
  • Pharmacology
  • Endocrinology

Background:

  • Moderate essential hypertension is a widespread condition requiring effective treatment.
  • Atrial natriuretic peptide (ANP) plays a role in cardiovascular homeostasis.
  • Selective AT1-blockers are used to manage hypertension.

Purpose of the Study:

  • To investigate the medium-term impact of irbesartan on plasma ANP levels.
  • To explore the relationship between irbesartan, blood pressure, and cardiac dimensions.

Main Methods:

  • A 30-day oral administration of irbesartan (300 mg daily) in patients with moderate essential hypertension.
  • Measurement of plasma ANP levels.
  • Monitoring of blood pressure and atrial/ventricular diameters.

Main Results:

  • Plasma ANP levels significantly increased by 15.7% after irbesartan treatment.
  • A reduction in blood pressure was observed.
  • A slight decrease in atrial and ventricular diameters was noted.

Conclusions:

  • Irbesartan, a selective AT1-blocker, elevates plasma ANP levels in hypertensive patients.
  • Increased ANP may contribute to the antihypertensive effects of irbesartan.
  • This study highlights a potential mechanism of action for AT1-blockers in managing hypertension.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...